News

Conference Coverage

Utilizing CAR T-Cell Therapy to Treat Patients With R/R Follicular Lymphoma

10/19/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Daniel Landsburg, MD, participated in a debate where he argued in favor of utilizing CAR T-cell therapy to treat patients with relapsed/refractory follicular lymphoma.

At the 2024 Lymphoma, Leukemia &...

10/19/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Use of Targeted Agents Among Patients With R/R Follicular Lymphoma

10/18/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Joanna Rhodes, MD, participated in a debate in which she discussed the use of novel therapies including targeted agents for treating patients with relapsed/refractory follicular lymphoma.

At the 2024 Lymphoma, Leukemia &...

10/18/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Using Lenalidomide and Rituximab, Tazemetostat, or Bispecific Antibodies to Treat Patients With Follicular Lymphoma

04/06/2024

Featuring Peter Martin, MD

During the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Peter Martin, MD, argued in favor of alternative treatment regimens over CAR T-cell therapy for treating follicular lymphoma.

During the 2024 Great Debates &...

04/06/2024

Oncology

Conference Coverage

Subcutaneous Mosunetuzumab Demonstrates Encouraging Efficacy, Manageable Safety as Frontline Therapy for High-Tumor Burden Follicular Lymphoma

01/12/2024

Lorenzo Falchi ;

At the 65th ASH Annual Meeting, Lorenzo Falchi, MD, shares results which indicated that subcutaneous mosunetuzumab as first-line therapy demonstrated efficacious outcomes and manageable safety among patients with high-tumor burden FL.

At the 65th ASH Annual Meeting,...

01/12/2024

Oncology

Conference Coverage

Updated Findings on Efficacy and Safety of Tazemetostat Plus Lenalidomide and Rituximab for Patients With R/R FL

01/10/2024

David J. Andorsky ;

At the 65th ASH Annual Meeting, David Andorsky, MD, discussed updated findings from the Symphony-1 trial after a 22.5-month follow-up.

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Conference Coverage

Prognostic Value of Undetectable MRD Status Among Patients With Follicular Lymphoma Post-Initial Treatment

01/10/2024

Alexey Danilov , MD;

At the 65th ASH Annual Meeting, Alexey Danilov, MD, analyzes the prognostic value of undetectable MRD among patients with follicular lymphoma initially treated with chemotherapy.

At the 65th ASH Annual Meeting,...

01/10/2024

Oncology

Conference Coverage

Rituximab Plus Lenalidomide Yields Favorable Outcomes Compared to Standard Regimen for Patients With Follicular Lymphoma

12/20/2023

Emanuele Zucca , MD;

At the 65th ASH Annual Meeting, Emanuele Zucca, MD, discussed long-term results from an updated analysis of the SAKK 35/10 trial, which indicated that rituximab plus lenalidomide therapy demonstrated durable efficacy among patients with...

At the 65th ASH Annual Meeting,...

12/20/2023

Oncology

Conference Coverage

Analyzing Response Rate and Line of Therapy Correlation Among Patients With R/R Follicular Lymphoma

12/10/2023

Tycel Phillips ;

At the 65th ASH Annual Meeting, Tycel Phillips, MD, discusses the relationship between the line of treatment, treatment site, and response rates among patients with follicular lymphoma with a poor prognosis, according to findings from a...

At the 65th ASH Annual Meeting,...

12/10/2023

Oncology

Sarah Rutherford, MD, Weill Cornell Medicine

Videos

CAR-T Therapy vs Other Novel Agents for Third-Line Treatment of FL

05/22/2022

Sarah Rutherford, MD, debates why she believes CAR-T therapy is the preferred treatment for patients with early progressing FL after 2 lines of prior therapy.

Sarah Rutherford, MD, debates...

05/22/2022

Oncology

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology